Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of FS-1502 in HER2-Expressing Advanced Solid Tumors and Breast Cancer
NCT03944499Phase 1Completed
- Sponsor
- Fosun Pharma
- Start
- Oct 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of caxmotabart entudotin in HER2-positive breast cancer and solid tumor, sponsored by Fosun Pharma. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 2 more. Started Oct 2019; status: completed.
02
Drugs
caxmotabart entudotin
03
Conditions
HER2-positive breast cancersolid tumor
Beyond the preview
Go deeper on NCT03944499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944499.